- Trial phase
- Phase 2
- Time to market
- At least 3-5 years away. BGE-102 is in Phase 2; even with positive data, Phase 3 trials and FDA review would take several years. The QUELL-DME trial results are not expected until H2 2027.
- Why 8/10
- The next hard, dated catalyst is the QUELL-CV Phase 2 topline data readout, expected in Q4 2026 (imminent, within ~2 months). BGE-102 is BioAge's lead asset and drives most of the company's valuation. The stock has fallen ~79% from its 52-week high, making this binary readout a potential make-or-break event for the near-term thesis.
The QUELL-CV Phase 2 topline data, expected in Q4 2026 (any day now through December), is the single most important catalyst. Positive data showing a clear dose-response on hsCRP and cardiometabolic biomarkers would validate BGE-102's best-in-class profile and likely drive a significant stock re-rating given the current depressed valuation. Negative or equivocal data would compound the sector skepticism from Novo Nordisk's failure and could pressure the stock further. QUELL-DME data in H2 2027 is a secondary catalyst.
Price Chart
Executive Summary
BGE-102 is BioAge Labs' lead asset, a novel oral NLRP3 inflammasome inhibitor in Phase 2 development for cardiovascular risk reduction and diabetic macular edema. Phase 1 data showed 85% median reductions in hsCRP (a key inflammation biomarker), positioning it as a potential best-in-class oral therapy. The stock trades at $5.34, down ~79% from its 52-week high of $25.96, after a July 2026 selloff triggered by disappointing Novo Nordisk cardiovascular data that raised sector-wide concerns about NLRP3-targeting approaches. The imminent QUELL-CV Phase 2 topline readout (expected Q4 2026) is the defining near-term catalyst. Analyst consensus is strongly bullish (12 Buy-equivalent ratings, 4 Hold, 0 Sell) with a mean price target of $32.56, implying ~510% upside. The company holds $352.3M in cash, sufficient through 2029.
How It Works
BGE-102 is an oral small molecule that inhibits the NLRP3 inflammasome, a protein complex inside immune cells that triggers inflammation. By blocking this pathway, the drug aims to reduce harmful chronic inflammation implicated in cardiovascular disease, obesity, and diabetic eye disease. It is taken as a once-daily pill.
Trial Status
Two Phase 2 trials are active. QUELL-CV (cardiovascular risk) has completed enrollment with topline data expected in Q4 2026. QUELL-DME (diabetic macular edema) dosed its first participant in September 2026, with topline results expected in the second half of 2027. Phase 1 single/multiple ascending dose data showed 85% median hsCRP reductions at 60mg and 120mg once-daily doses in participants with obesity and elevated baseline inflammation, with good tolerability.
The Two-Sided Case
Upcoming Catalysts
- QUELL-CV Phase 2 topline data expected Q4 2026 (imminent)
- APJ agonist program IND submission on track for year-end 2026
- QUELL-DME Phase 2 topline results expected H2 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioAge Labs, Inc. PRESS-RELEASE BIOA ·Originating report